PubMed Health⌕ Search

Biomedical subjects

L C Fuith

Publications and source records attributed to L C Fuith.

At least 37 records · Page 2Linked to original sources
PubMed1989

[Tumor markers in gynecology].

The employment of tumour markers in gynaecology has gained increasing importance in recent times. Beta HCG for chorionic carcinoma and alpha 1 fetoprotein for germ cell tumours are an essential part of postoperative surveillance. Initial analyses of the amylase isoenzymes are available. CEA, TPA, and CA 125 are recognized as established tumour markers. Very promising results have been obtained using SCC in patients with cervical carcinoma. Neopterin, a marker for cell-mediated immunity, provides good prognostic information.

Biomarkers, Tumor↗
PubMed1989

[Severe bacterial infections in gynecology and obstetrics].

Within a 3-years period the presence of nosocomial bacteriaemias was analyzed retrospectively among 13.878 hospitalized patients. The incidence was 0.050%. Antibiotic prophylaxis and the operative technique play an important role in achieving a low incidence of morbidity due to infection. The management of a severe infection includes antibiotic therapy according to culture sensitivity and intensive care.

Ampicillin↗
PubMed1989

CA 125 in human milk and serum.

CA 125 serum concentrations drawn immediately following delivery exceeded 35 U/ml in all cases (median 276 U/ml). One week post partum elevations of CA 125 were still found, but the median level decreased to 45 U/ml. Six weeks after parturition no positivity was detected in the serum (median 12 U/ml). Considerable CA 125 levels were present in the human milk 1 week after delivery (median 208 U/ml). CA 125 was still found in the milk after 6 weeks (median 153 U/ml). We conclude that positive CA 125 concentrations in the serum after parturition derive from an antigen transfer to the maternal circulation during the placental separation. Furthermore, CA 125 seems to be synthesized by the lactating breast.

Adolescent↗
PubMed1989

Effects of interferon-alpha on macrophage activation in patients with ovarian carcinoma and cervical dysplasia.

Patients with progressive ovarian carcinoma and patients with dysplasia of the uterine cervix were studied in order to compare clinical efficacy, hematological toxicity and effects on macrophage activation of administered interferon-alpha for both patient groups. One of three patients with ovarian carcinoma showed a minor response. Four of six patients with cervical dysplasia had slight improvements of PAP-smears. Moderate hematological toxicity was observed in the former patient group while side effects were much more pronounced in the latter patients group. However, changes of hematological parameters were not statistically different. Interestingly, the administered interferon-alpha caused the same activation of macrophages in both patients groups as indicated by raised neopterin levels. This activation does not result in clinical improvement but appears to play a role for the hematological toxicity observed during therapy of patients with ovarian carcinoma. It has been suggested that suppression of hematopoiesis is mediated by interferon-gamma. The present neopterin data propose that this lymphokine is continuously produced through influence of the tumor and enhanced by interferon-alpha.

Adult↗
PubMed1988

Combination chemotherapy with epirubicin and cisplatin in ovarian carcinoma.

Combination chemotherapy with epirubicin-cisplatin was employed after surgical treatment in 67 women with ovarian carcinoma. 50 mg/m2 of epirubicin and cisplatin each were administered at monthly intervals. The response rate was correlated with the clinical stage and the residual disease. Tumor regression (CR + PR) was observed in 63.6% of patients with stage III disease, and in 50% of those with stage IV disease. Furthermore, complete or partial responses were obtained in 86.4% of patients with a residual deposit of 2-5 cm, and in 33.3% of women with a residual deposit exceeding 5 cm in diameter. Anemia occurred in 47.8%, leukopenia in 43.3%, and thrombocytopenia in 4.5% of the patients. No cardiotoxicity was recorded.

Adult↗
PubMed1988

[Multiple cancers in gynecologic oncology].

An analysis of 97 patients with multiple primary gynaecological neoplasms (90 double-, 6 triple- and 1 quadruple carcinomas) was done at the Gynaecological Department of the University of Innsbruck. Two thirds of the tumour combinations were located in the female genital tract including the breast. Concerning the early detection of simultaneous or subsequent malignancies of the cervix or corpus uteri, one should pay attention to the mamma being involved in the treatment or aftercare of such cancers. In the same way the inner female genital tract has to be observed in breast cancer patients. Regular colposcopic and cytological examinations of the cervical portio as well as a systematic prevention of endometrial cancer (pistolet in local anaesthesia) is highly recommended. The prognosis of the "highly malignant" tumour does not worsen as a result of a second malignant cancer.

Breast Neoplasms↗